MCID: HMG002
MIFTS: 49

Hemoglobinuria

Categories: Blood diseases, Immune diseases, Nephrological diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hemoglobinuria

Summaries for Hemoglobinuria

MalaCards based summary: Hemoglobinuria is related to paroxysmal nocturnal hemoglobinuria and aplastic anemia, and has symptoms including chyluria and other and unspecified genitourinary symptoms. An important gene associated with Hemoglobinuria is PIGA (Phosphatidylinositol Glycan Anchor Biosynthesis Class A), and among its related pathways/superpathways are Metabolism of proteins and Innate Immune System. The drugs Miconazole and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and myeloid, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia: 75 Hemoglobinuria is a condition in which the oxygen transport protein hemoglobin is found in abnormally... more...

Related Diseases for Hemoglobinuria

Diseases related to Hemoglobinuria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 510)
# Related Disease Score Top Affiliating Genes
1 paroxysmal nocturnal hemoglobinuria 32.1 PIGT PIGA HP G6PD FCGR3B CSF3
2 aplastic anemia 31.4 PIGA EPO CSF3 CD59 CD58 CD55
3 blackwater fever 31.4 MB HP G6PD
4 blood group, globoside system 31.2 CSF3 CFI C3
5 myelodysplastic syndrome 31.0 PIGA FCGR3B EPO CSF3 CD59 CD55
6 thrombophilia due to thrombin defect 30.9 THBD SERPINC1 F2
7 pancytopenia 30.9 HP F2 EPO CSF3 CD55
8 acute kidney failure 30.7 MB HP F2
9 budd-chiari syndrome 30.7 SERPINC1 PIGA F2 CD59 CD55
10 refractory anemia 30.7 EPO CSF3
11 thrombophilia 30.6 THBD SERPINC1 F2
12 thrombosis 30.5 THBD SERPINC1 F2 EPO CD55
13 multiple congenital anomalies-hypotonia-seizures syndrome 2 30.4 PIGT PIGA CD59
14 portal vein thrombosis 30.3 THBD SERPINC1 F2
15 anemia, autoimmune hemolytic 30.3 HP G6PD EPO CD59 CD55 C3
16 d-minus hemolytic uremic syndrome 30.2 CFI C3
17 purpura 30.2 THBD SERPINC1 F2 C3
18 pure red-cell aplasia 30.1 HP EPO CSF3
19 hemolytic anemia 30.1 THBD PIGT PIGA HP G6PD EPO
20 leukemia, chronic lymphocytic 30.1 FCGR3B CSF3 CR1 CD59 CD58 CD55
21 hereditary spherocytosis 30.0 HP G6PD EPO
22 splenic infarction 30.0 SERPINC1 HP F2
23 chronic kidney disease 30.0 THBD HP EPO CFI
24 congenital dyserythropoietic anemia 30.0 CD59 CD58 CD55
25 membranous nephropathy 29.9 HP CR1 CD59
26 severe pre-eclampsia 29.9 SERPINC1 HP F2
27 hypersplenism 29.9 SERPINC1 F2 EPO CSF3
28 chickenpox 29.8 FCGR3B F2 CSF3
29 severe covid-19 29.8 FCGR3B F2 CSF3
30 esophageal varix 29.8 SERPINC1 HP F2
31 varicose veins 29.8 THBD SERPINC1 F2
32 sagittal sinus thrombosis 29.8 SERPINC1 F2
33 splenic sequestration 29.7 HP F2 EPO
34 central retinal artery occlusion 29.7 SERPINC1 F2
35 anuria 29.7 MB HP F2
36 lemierre's syndrome 29.6 SERPINC1 F2
37 disseminated intravascular coagulation 29.6 THBD SERPINC1 MB F2
38 congenital hemolytic anemia 29.6 HP G6PD EPO
39 thalassemia 29.6 HP G6PD F2 EPO
40 thrombotic thrombocytopenic purpura 29.6 THBD SERPINC1 HP CFI
41 deficiency anemia 29.6 SERPINC1 MB HP G6PD F2 EPO
42 thrombocytopenia 29.6 THBD SERPINC1 HP F2 EPO CSF3
43 antiphospholipid syndrome 29.5 THBD SERPINC1 F2 C3
44 intracranial embolism 29.5 SERPINC1 F2
45 glomerulonephritis 29.5 CR1 CFI CD59 CD55 C3
46 thrombophilia due to activated protein c resistance 29.5 THBD SERPINC1 F2
47 pulmonary embolism 29.5 THBD SERPINC1 MB F2
48 gilbert syndrome 29.5 HP G6PD F2
49 acute myocardial infarction 29.4 THBD SERPINC1 MB F2
50 end stage renal disease 29.4 THBD EPO CFI C3

Graphical network of the top 20 diseases related to Hemoglobinuria:



Diseases related to Hemoglobinuria

Symptoms & Phenotypes for Hemoglobinuria

UMLS symptoms related to Hemoglobinuria:


chyluria; other and unspecified genitourinary symptoms

GenomeRNAi Phenotypes related to Hemoglobinuria according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.2 BST1 C3 C5 CD55 CD58 CD59
2 no effect GR00402-S-2 10.2 C3 C5 CD55 CD58 CD59 CFI

MGI Mouse Phenotypes related to Hemoglobinuria:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 C3 C5 CD55 CD59 CFI CR1
2 immune system MP:0005387 10.06 BST1 C3 C5 CD55 CD59 CFI
3 renal/urinary system MP:0005367 9.97 C3 CD55 CD59 CFI CR1 CSF3
4 hematopoietic system MP:0005397 9.86 BST1 C3 CD55 CD59 CFI CR1
5 mortality/aging MP:0010768 9.5 C3 C5 CD55 CD59 CR1 EPO

Drugs & Therapeutics for Hemoglobinuria

Drugs for Hemoglobinuria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
2
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
3
Warfarin Approved Phase 4 81-81-2, 129-06-6 54678486
4
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
5
Ravulizumab Approved, Investigational Phase 4 1803171-55-2
6 Antifungal Agents Phase 4
7 Anticoagulants Phase 4
8 Immunosuppressive Agents Phase 4
9 Immunologic Factors Phase 4
10
Temazepam Approved, Investigational Phase 3 846-50-4 5391
11
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
12
Iodine Approved, Investigational Phase 3 7553-56-2 807
13
Rituximab Approved Phase 3 174722-31-7
14
Protein C Approved Phase 3
15
Eculizumab Approved, Investigational Phase 3 219685-50-4
16 Antirheumatic Agents Phase 3
17 Cyclosporins Phase 3
18 Antibodies, Monoclonal Phase 3
19 Alkylating Agents Phase 3
20 Antineoplastic Agents, Alkylating Phase 3
21 Antilymphocyte Serum Phase 3
22
Muromonab-CD3 Phase 3
23 Pharmaceutical Solutions Phase 3
24 Chrysarobin Phase 3
25 Complement System Proteins Phase 3
26 Immunoglobulins Phase 3
27 Antibodies Phase 3
28
Levamisole Approved, Investigational, Vet_approved, Withdrawn Phase 2 14769-73-4 26879
29
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
30
Lenograstim Approved, Investigational Phase 2 135968-09-1
31
Mycophenolic acid Approved, Investigational Phase 2 24280-93-1 446541
32
Melphalan Approved Phase 2 148-82-3 4053 460612
33
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
34
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
35
Tannic acid Approved Phase 2 1401-55-4 16129878 16129778
36
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
37
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
38
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
39
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
40
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
41
Basiliximab Approved, Investigational Phase 2 179045-86-4
42
Coenzyme M Approved, Investigational Phase 2 3375-50-6 598 23662354
43
Busulfan Approved, Investigational Phase 2 55-98-1 2478
44
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 4112 126941
45
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
46
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643
47
Treosulfan Approved, Investigational Phase 2 299-75-2 9296
48
D-Phenylalanine Approved, Experimental, Investigational, Nutraceutical Phase 2 63-91-2, 673-06-3 6140 71567
49
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
50
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7 4897

Interventional clinical trials:

(show top 50) (show all 120)
# Name Status NCT ID Phase Drugs
1 Sirolimus Combined With Low-dose Warfarin for the Treatment of Refractory Classic Paroxysmal Nocturnal Hemoglobinuria ,a Prospective Study Unknown status NCT03866681 Phase 4 sirolimus
2 An Open-Label Multi-Center Study of Eculizumab in Children and Adolescents With a Diagnosis of Paroxysmal Nocturnal Hemoglobinuria Completed NCT00867932 Phase 4 Eculizumab
3 Phase 4, Single-Arm Study of Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab Active, not recruiting NCT04320602 Phase 4
4 A Multicenter, Open Label, Randomized, Parallel-group Study of Efficacy and Safety of Eculizumab (JSC GENERIUM, Russia) vs. Soliris® (Alexion Pharma GmbH, Switzerland) in Patients With Paroxysmal Nocturnal Hemoglobinuria Completed NCT04463056 Phase 3
5 An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria Completed NCT04162470 Phase 3 REGN3918
6 A Randomized, Double-Blind, Active-Controlled Phase 3 Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed NCT03818607 Phase 3 ABP 959;Eculizumab
7 A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation) in Patients With Paroxysmal Nocturne Hemoglobinuria, Who Have Been Involved Earlier in the Clinical Trials of Eculizumab Completed NCT04679103 Phase 3
8 A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab Completed NCT03056040 Phase 3
9 A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed NCT04085601 Phase 3 APL-2
10 Hematopoietic Stem Cell Transplantation Using Matched Unrelated Donor Peripheral Blood or Bone Marrow for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
11 A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Completed NCT00098280 Phase 3 Eculizumab
12 Randomized, Double-Blind, and Placebo-Controlled Study Using Eculizumab in Transfusion Dependent PNH Patients Completed NCT00122330 Phase 3 eculizumab
13 A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed NCT03406507 Phase 3
14 Investigational Product ; Coversin. Phase III Safety and Efficacy in Three-Part, Two-Arm, Randomised Open Label Evaluation in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH) Completed NCT03588026 Phase 3 rVA576
15 Haploidentical Stem Cell Transplantation Utilizing Purified CD34+ Hematopoietic Cells for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
16 Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH Completed NCT00122317 Phase 3 eculizumab
17 Safety in Hemolytic PNH Patients Treated With Eculizumab: a Multi-Center Open-Label Research Design Study Completed NCT00122304 Phase 3 eculizumab
18 TRIUMPH: A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Completed NCT00112983 Phase 3
19 SHEPHERD: Safety in Hemolytic PNH Patients Treated With Eculizumab: A Multi-Center Open-Label Research Design Completed NCT00130000 Phase 3 Eculizumab
20 Randomized, Open-Label, International, Multi-center, Comparative Study of Efficacy and Safety of BCD-148 (JSC BIOCAD, Russia) and Soliris® in Patients With Paroxysmal Nocturnal Hemoglobinuria Completed NCT04060264 Phase 3
21 A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB12 (Proposed Eculizumab Biosimilar) and Soliris® in Subjects With Paroxysmal Nocturnal Haemoglobinuria Completed NCT04058158 Phase 3 SB12 (proposed eculizumab biosimilar);Soliris (eculizumab)
22 A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed NCT03500549 Phase 3 Pegcetacoplan;Soliris
23 Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition To Anti-Thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome Completed NCT00774527 Phase 3 Cyclophosphamide-fludarabine-anti thymocyte globulin
24 An Open Label, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Completed PNH Phase 2 and Phase3 Studies With Iptacopan Recruiting NCT04747613 Phase 3 Iptacopan
25 A Randomized, Open-Label, Ravulizumab-Controlled,Non-Inferiority Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy Recruiting NCT05133531 Phase 3 Ravulizumab;Pozelimab;Cemdisiran
26 A Randomized, Open-Label, Eculizumab and Ravulizumab Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Currently Treated With Eculizumab or Ravulizumab Recruiting NCT05131204 Phase 3 Cemdisiran;Eculizumab;Pozelimab;Ravulizumab
27 A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating The Safety, Pharmacokinetics, Pharmacodynamic And Efficacy of Crovalimab Versus Eculizumab In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors Recruiting NCT04432584 Phase 3 Crovalimab;Eculizumab
28 A Phase III, Multicenter, Single Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition Active, not recruiting NCT04654468 Phase 3 Crovalimab
29 A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label, Pharmacokinetic, Noninferiority Study of Ravulizumab Administered Subcutaneously Versus Intravenously in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With Eculizumab Active, not recruiting NCT03748823 Phase 3
30 A Randomized, Multicenter, Active-comparator Controlled, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult Patients With PNH and Residual Anemia, Despite Treatment With an Intravenous Anti-C5 Antibody. Active, not recruiting NCT04558918 Phase 3 LNP023;Eculizumab;Ravulizumab
31 A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors. Active, not recruiting NCT04434092 Phase 3 Crovalimab;Eculizumab
32 A Multicenter, Single-arm, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily Iptacopan in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy Active, not recruiting NCT04820530 Phase 3 Iptacopan (LNP023)
33 A Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 Inhibitor (Eculizumab or Ravulizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Evident Extravascular Hemolysis (EVH) Active, not recruiting NCT04469465 Phase 3 Danicopan;Placebo;C5 Inhibitor
34 A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Active, not recruiting NCT02946463 Phase 3
35 An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) Active, not recruiting NCT03531255 Phase 3 Pegcetacoplan
36 A Multicenter, Single Arm, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily Iptacopan in Adult PNH Patients Who Have Hb≥10 g/dL in Response to Anti-C5 Antibody and Switch to Iptacopan Not yet recruiting NCT05630001 Phase 3 Iptacopan
37 A Long-term Extension (LTE) Study to Characterize the Safety and Efficacy of Danicopan as an Add-on Therapy to a Complement Component 5 Inhibitor (C5i) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Previously Treated With Danicopan in an Alexion-sponsored Clinical Study Not yet recruiting NCT05389449 Phase 3 Danicopan
38 CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study Terminated NCT03829449 Phase 3 rVA576 (Coversin)
39 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria Unknown status NCT01642979 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
40 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) Unknown status NCT01760096 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
41 A Phase 1 Dose-ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of BCX9930 in Healthy Subjects and in Subjects With Paroxysmal Nocturnal Hemoglobinuria Completed NCT04330534 Phase 1, Phase 2 BCX9930;Placebo
42 A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of ACH-0144471 in Untreated Patients With Paroxysmal Nocturnal Hemoglobinuria Completed NCT03053102 Phase 2 Danicopan
43 A Multi-center, Randomized, Open-label, Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria and Active Hemolysis Completed NCT03896152 Phase 2 LNP023
44 A Phase 2 Multicenter, Open-Label, Uncontrolled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Have an Inadequate Response to Eculizumab Completed NCT03030183 Phase 2 Zilucoplan (RA101495)
45 Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial Completed NCT00397813 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
46 A Phase 2, Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria Completed NCT02605993 Phase 2
47 An Open-Label, Intrapatient, Dose-Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria Completed NCT02598583 Phase 1, Phase 2
48 Phase 2 Multicenter, Open-Label, Uncontrolled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Completed NCT03078582 Phase 2 Zilucoplan (RA101495)
49 Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms Completed NCT02591862 Phase 2 Coversin
50 HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR PATIENTS WITH BONE MARROW FAILURE SYNDROME - A PHASE 2 STUDY Completed NCT00731328 Phase 2

Search NIH Clinical Center for Hemoglobinuria

Cochrane evidence based reviews: hemoglobinuria

Genetic Tests for Hemoglobinuria

Genetic tests related to Hemoglobinuria:

# Genetic test Affiliating Genes
1 Hemoglobinuria 28

Anatomical Context for Hemoglobinuria

Organs/tissues related to Hemoglobinuria:

MalaCards : Bone Marrow, Bone, Myeloid, T Cells, Kidney, Monocytes, Neutrophil

Publications for Hemoglobinuria

Articles related to Hemoglobinuria:

(show top 50) (show all 3750)
# Title Authors PMID Year
1
The prevalence of G6PD deficiency in blood transfusion recipients. 53 62
17364999 2007
2
[Post-hemolytic renal failure in children with glucose-6-phosphate dehydrogenase deficiency at the University Hospital Center in Lome]. 53 62
12910652 2003
3
Ethanol sclerotherapy of venous malformations: evaluation of systemic ethanol contamination. 53 62
11340138 2001
4
Acute myelogenous leukemia with PIG-A gene mutation evolved from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome. 53 62
11372733 2001
5
Paroxysmal nocturnal hemoglobinuria: An acquired genetic disease. 53 62
10539884 1999
6
Paroxysmal nocturnal hemoglobinuria: molecular pathogenesis and molecular therapeutic approaches. 53 62
9844822 1998
7
Blackwater fever in southern Vietnam: a prospective descriptive study of 50 cases. 53 62
8953071 1996
8
Serum transcobalamin II level in glucose-6-phosphate dehydrogenase deficient subjects with typhoid fever. 53 62
8708525 1996
9
Persistently elevated serum transcobalamin II in a patient with cerebral malaria and typhus infections. 53 62
7622977 1995
10
Repeated large-dose haptoglobin therapy in an extensively burned patient: case report. 53 62
8163802 1994
11
Hemolytic effect of the Amplatz thrombectomy device. 53 62
8136596 1994
12
[Intensive care of a postpartum patient complicated with HELLP syndrome]. 53 62
8320814 1993
13
Regulation of renal function in thermal injury. 53 62
2147724 1990
14
[Administration of haptoglobin in ABO incompatible bone marrow transplantation]. 53 62
2255063 1990
15
Clinical characteristics of 512 eculizumab-naive paroxysmal nocturnal hemoglobinuria patients in China: a single-center observational study. 62
35068377 2022
16
Monocyte subset analysis in the presence of paroxismal nocturnal hemoglobinuria. A case report. 62
35438826 2022
17
Exertional hemolysis and hematuria in a Labrador Retriever dog. 62
36184929 2022
18
Management of paroxysmal nocturnal hemoglobinuria (PNH). 62
36378554 2022
19
Immunophenotypic assessment of PNH clones in major and minor cell lineages in the peripheral blood of patients with paroxysmal nocturnal hemoglobinuria. 62
36134740 2022
20
The first successful expanded compassionate use of Iptacopan in a patient with paroxysmal nocturnal hemoglobinuria. 62
35965286 2022
21
Dimethyl Sulfoxide Induces Hemolysis and Pulmonary Hypertension. 62
36473034 2022
22
Feasibility of electronic patient-reported outcome monitoring and self-management program in aplastic anemia and paroxysmal nocturnal hemoglobinuria-a pilot study (ePRO-AA-PNH). 62
36326854 2022
23
Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway. 62
36369963 2022
24
March hemoglobinuria progressed to acute kidney injury after kendo practice: a case report. 62
36384502 2022
25
Clinical significance of the increased expression of the WT1 gene in peripheral blood of patients with acquired aplastic anemia. 62
36467821 2022
26
Scaffold hopping via ring opening enables identification of acyclic compounds as new complement Factor D inhibitors. 62
36272185 2022
27
Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi-protein cascade of the complement system. 62
36398537 2022
28
Low-molecular weight inhibitors of the alternative complement pathway. 62
36217774 2022
29
Molecular landscape of immune pressure and escape in aplastic anemia. 62
36253429 2022
30
"All renal manifestations of paroxysmal nocturnal hemoglobinuria in one patient". 62
35349002 2022
31
From magic bullets to modern therapeutics: Paul Ehrlich, the German immunobiologist and physician coined the term 'complement'. 62
36027818 2022
32
Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up. 62
36272026 2022
33
COVID-19 and the antiphospholipid syndrome. 62
36195247 2022
34
A novel promising diagnostic candidate selected by screening the transcriptome of Babesia gibsoni (Wuhan isolate) asexual stages in infected beagles. 62
36217160 2022
35
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs. 62
36117056 2022
36
With complements: C3 inhibition in the clinic. 62
36161656 2022
37
The cost-effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK setting. 62
35796199 2022
38
Portal vein thrombosis as the first presentation of paroxysmal nocturnal hemoglobinuria. 62
35989282 2022
39
Paroxysmal Nocturnal Hemoglobinuria: Experience of compassionate use pegcetacoplan. 62
36054920 2022
40
Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies. 62
35502600 2022
41
Successful management of unstable angina in a ravulizumab-treated patient with paroxysmal nocturnal hemoglobinuria. 62
36130907 2022
42
Concomitant Immunosuppressive Therapy and Eculizumab Use in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): An International PNH Registry Analysis. 62
36108594 2022
43
Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real-world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry. 62
35390189 2022
44
Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria. 62
35869170 2022
45
Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study. 62
35869984 2022
46
Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. 62
36054881 2022
47
The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target. 62
36110036 2022
48
Vasculitic Moyamoya syndrome in a patient with paroxysmal nocturnal hemoglobinuria: A case report and literature review. 62
35815532 2022
49
[Congenital hemolytic anemias due to erythrocyte membrane and enzyme defects]. 62
36126925 2022
50
Subacute stent thrombosis with spontaneously resolved secondary thrombi in paroxysmal nocturnal hemoglobinuria: a case report. 62
36096718 2022

Variations for Hemoglobinuria

Expression for Hemoglobinuria

Search GEO for disease gene expression data for Hemoglobinuria.

Pathways for Hemoglobinuria

Pathways related to Hemoglobinuria according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.66 SERPINC1 PIGT PIGH PIGA FCGR3B F2
2
Show member pathways
13.65 BST1 C3 C5 CD55 CD58 CD59
3
Show member pathways
12.26 F2 CR1 CFI CD59 CD55 C5
4
Show member pathways
11.96 THBD SERPINC1 F2 CR1 CFI CD55
5
Show member pathways
11.73 CD59 CD55 C5 C3
6 11.72 EPO CSF3 CD59
7
Show member pathways
11.72 PIGT PIGH PIGA FCGR3B BST1
8 11.6 CD55 C5 C3
9
Show member pathways
11.13 CR1 CFI CD59 CD55 C5 C3
10 10.4 C5 C3

GO Terms for Hemoglobinuria

Cellular components related to Hemoglobinuria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.3 C3 C5 CD59 CFI CR1 CSF3
2 extracellular region GO:0005576 10.22 BST1 C3 C5 CD55 CD59 CFI
3 cell surface GO:0009986 10.21 C3 CD55 CD58 CD59 CR1 EPO
4 blood microparticle GO:0072562 10.01 SERPINC1 HP F2 C3
5 ficolin-1-rich granule membrane GO:0101003 9.93 CR1 CD58 CD55
6 secretory granule membrane GO:0030667 9.92 FCGR3B CR1 CD58 CD55
7 extracellular exosome GO:0070062 9.77 BST1 C3 C5 CD55 CD58 CD59
8 glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex GO:0000506 9.73 PIGH PIGA
9 obsolete anchored component of membrane GO:0031225 9.26 FCGR3B CD59 CD55 BST1

Biological processes related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.04 C3 C5 CD55 CFI CR1 HP
2 acute-phase response GO:0006953 9.95 HP F2 EPO
3 blood coagulation GO:0007596 9.92 THBD SERPINC1 F2 CD59
4 negative regulation of complement activation, classical pathway GO:0045959 9.86 CR1 CD55
5 negative regulation of platelet activation GO:0010544 9.84 THBD F2
6 regulation of complement activation GO:0030449 9.83 CD59 CD55
7 GPI anchor biosynthetic process GO:0006506 9.83 PIGT PIGH PIGA
8 regulation of complement-dependent cytotoxicity GO:1903659 9.81 CD59 CD55
9 negative regulation of complement activation GO:0045916 9.71 CD55 CR1
10 complement activation GO:0006956 9.67 CFI C5 C3
11 hemostasis GO:0007599 9.63 THBD SERPINC1 F2
12 negative regulation of activation of membrane attack complex GO:0001971 9.56 CR1 CD59
13 positive regulation of response to stimulus GO:0048584 9.55 C5 C3
14 positive regulation of activation of membrane attack complex GO:0001970 9.46 CR1 C3
15 complement activation, alternative pathway GO:0006957 9.43 CR1 C5 C3
16 complement activation, classical pathway GO:0006958 9.32 CR1 CFI CD55 C5 C3

Sources for Hemoglobinuria

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....